Evidence map›Paper›PMID 31602564›Full record

ReviewDrugs2019

Fixed and Low-Dose Combinations of Blood Pressure-Lowering Agents: For the Many or the Few?

Massimo Leggio, Augusto Fusco, Claudia Loreti, Giorgio Limongelli, Maria Grazia Bendini, Andrea Mazza, Antonio Frizziero, Daniele Coraci, Luca Padua

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Massimo LeggioCardiology Operative Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.
Augusto FuscoIRCCS Fondazione Don Carlo Gnocchi, P.le Rodolfo Morandi, 6, 20121, Milan, Italy. afusco@dongnocchi.it.ORCID http://orcid.org/0000-0002-8528-7834
Claudia LoretiIRCCS Fondazione Don Carlo Gnocchi, P.le Rodolfo Morandi, 6, 20121, Milan, Italy.
Giorgio LimongelliCardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy.
Maria Grazia BendiniCardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy.
Andrea MazzaCardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy.
Antonio FrizzieroDepartment of Physical and Rehabilitation Medicine, University of Padova, Padua, Italy.
Daniele CoraciFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Luca PaduaDepartment of Geriatrics, Neuroscience and Orthopedics, Catholic University of the Sacred Heart, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the widespread availability of several effective classes of drugs, systemic arterial hypertension remains poorly controlled in the majority of patients worldwide. In this article, we discuss the different modalities and effects of combination therapy and possible future research questions. Treatment with a single antihypertensive agent can effectively reduce blood pressure in only a limited number of patients, while most require therapy with two or more agents to achieve target levels. As initial therapy, American and European guidelines suggest a combination of two antihypertensive drugs and the use of a third antihypertensive drug when hypertension is still uncontrolled. Initial combination therapy is recommended in high-risk patients for an immediate blood pressure response, improved tolerability and possibly increased patient adherence. In addition to the potential benefits of combining different drug classes with synergistic pharmacological and physiological actions, this approach is useful for increasing the patient compliance with treatment, in particular if provided at fixed doses in a single pill. The minimisation of side effects is critical for the long-term treatment of a largely asymptomatic condition such as systemic hypertension. Low-dose combinations of different drugs from classes with complementary actions may provide the best ratio of lower side effects and improved tolerability with a significant blood pressure reduction, particularly in high-risk patients. This approach could be aided by a multidisciplinary lifestyle intervention on risk factors.

Indexed as

AnimalsAntihypertensive AgentsBlood PressureBlood Pressure DeterminationDose-Response Relationship, DrugDrug Therapy, CombinationHumansAntihypertensive Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.